Our strategy is to develop and put into market a series of cell medicine that can be administrated on patients who need innovative treatment options. Our mass-produced cell medicine are resourced from placenta and umbilical cord. These cell products do not require genetic or tissue matching prior to administration and could be delivered in almost any clinical setting. We have designed injections and externally applied agents to target a variety of indications, and will develop a pipeline of differentiated products for various indications.
We intend to use our first-mover advantage in Chinese market, and build affiliations with hospitals, to develop a commercialization path for our therapies.
For more information about partnering opportunities please contact us at： hb@health-biomed.com
